Literature DB >> 2999235

Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells.

B A Beutler, A Cerami.   

Abstract

Recombinant murine interleukin 1 (rIL 1) inhibits 3T3-L1 cell expression of lipoprotein lipase (LPL) activity when present in exceedingly dilute concentration (less than 10(-15) M). The extreme sensitivity of the adipocyte system to rIL 1 far exceeds that of the standard lymphocyte-activating factor assay. However, enzyme suppression is incomplete; even at micromolar concentrations, rIL 1 causes only about a 50% reduction in LPL activity. By contrast, cachectin (tumor necrosis factor) achieves nearly complete LPL suppression at subnanomolar concentrations. Concentrated solutions of rIL 1 are incapable of competing with radiolabeled cachectin for binding sites on 3T3-L1 cells. rIL 1-induced LPL suppression is abolished by the addition of a specific IL 1 neutralizing antiserum to the assay system. rIL 1 appears capable of influencing adipocyte expression of LPL, but apparently acts through a different mechanism than cachectin/TNF.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2999235

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  57 in total

1.  Dyslipoproteinemia during the active course of systemic lupus erythematosus in association with anti-double-stranded DNA (anti-dsDNA) antibodies.

Authors:  Sara Kashef; Mohammad Mehdi Ghaedian; Akbar Rajaee; Abbas Ghaderi
Journal:  Rheumatol Int       Date:  2006-08-30       Impact factor: 2.631

2.  Response of bone marrow stromal cells to adipogenic antagonists.

Authors:  J M Gimble; M A Dorheim; Q Cheng; P Pekala; S Enerback; L Ellingsworth; P W Kincade; C S Wang
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

3.  Regulation of lipoprotein lipase activity and mRNA content in rat epididymal adipose tissue in vitro by recombinant tumour necrosis factor.

Authors:  A G Mackay; J D Oliver; M P Rogers
Journal:  Biochem J       Date:  1990-07-01       Impact factor: 3.857

Review 4.  The role of tumor necrosis factor and interleukin 1 in the immunoinflammatory response.

Authors:  J W Larrick; S L Kunkel
Journal:  Pharm Res       Date:  1988-03       Impact factor: 4.200

5.  Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression.

Authors:  D H Perlmutter; C A Dinarello; P I Punsal; H R Colten
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

6.  Recombinant interleukin-1 alpha and recombinant tumor necrosis factor alpha synergize in vivo to induce early endotoxin tolerance and associated hematopoietic changes.

Authors:  S N Vogel; E N Kaufman; M D Tate; R Neta
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

7.  Recombinant human cachectin/tumor necrosis factor but not interleukin-1 alpha downregulates lipoprotein lipase gene expression at the transcriptional level in mouse 3T3-L1 adipocytes.

Authors:  R Zechner; T C Newman; B Sherry; A Cerami; J L Breslow
Journal:  Mol Cell Biol       Date:  1988-06       Impact factor: 4.272

8.  Role of caspase-1 in regulation of triglyceride metabolism.

Authors:  Maya E Kotas; Michael J Jurczak; Charles Annicelli; Matthew P Gillum; Gary W Cline; Gerald I Shulman; Ruslan Medzhitov
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-04       Impact factor: 11.205

9.  Plasma lipids and lipoproteins in juvenile chronic arthritis.

Authors:  A Bakkaloglu; B Kirel; S Ozen; U Saatçi; N Beşbaş
Journal:  Clin Rheumatol       Date:  1996-07       Impact factor: 2.980

10.  Tumor necrosis factor mediates endotoxic effects in mice.

Authors:  F Bauss; W Dröge; D N Männel
Journal:  Infect Immun       Date:  1987-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.